Health TrialsbyHealthPanel

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Participants needed: 280
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Oct 8, 2026Locations: 26
Eligibility criteria

Signed the informed consent form voluntarily and agreed to follow the program re... [+36]

Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted... [+27]

Read more
Status: Not yet recruiting

SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.

Participants needed: 424
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Oct 5, 2026Locations: 7
Eligibility criteria

Documented locally advanced or metastatic solid tumor(s) not amenable to curativ... [+3]

Chemotherapy, biological therapy, immunotherapy, targeted therapy (including sma... [+21]

Read more
Status: Recruiting

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Participants needed: 550
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Sep 17, 2026Locations: 62
Eligibility criteria

Histologically or cytologically confirmed first-line (1L), extensive-stage (ES)... [+4]

Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC... [+5]

Read more
Status: Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Sep 16, 2026Locations: 24
Eligibility criteria

Documented locally advanced or metastatic SCLC, large cell neuroendocrine cancer... [+8]

Chemotherapy, biological therapy, immunotherapy, , targeted therapy (including s... [+8]

Read more
Status: Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Participants needed: 540
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Sep 21, 2026Locations: 37
Eligibility criteria

Signed the informed consent voluntarily and agreed to follow the program require... [+26]

Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted... [+25]

Read more